Although antifibrotic drugs, including nintedanib and pirfenidone, slow the progression of idiopathic pulmonary fbrosis (IPF), there is little data about the timing of start of antifibrotic treatment in real-world clinical practice. The present study aimed to clarify the efficacy of nintedanib and pirfenidone in patients with early-stage IPF. |